Are non-cancer diagnoses missed opportunities in diagnosing cancer? Observational case-control studies
Background Initial non-cancer diagnoses that plausibly explain cancer symptoms may be underexplored missed opportunities in cancer diagnosis. Aim To characterise "interim diagnoses" representing potential missed opportunities to diagnose cancer; namely, non-cancer conditions diagnosed before cancer that are associated both with cancer and better and/or worse cancer outcomes. Design and Setting Observational case-control and case-only analyses of registry-linked Clinical Practice Research Datalink data from English primary care. Methods Cancer cases (cancer registry diagnoses, 1/1/2012-31/12/2018) were matched to cancer-free controls on birth year, gender and general practice. Incident non-cancer diagnoses sharing cancer symptoms were sought in the year before the case's diagnosis. Conditional logistic regression characterised non-cancer diagnoses associated with cancer (Bonferroni-corrected p<0.05). Associations between non-cancer diagnoses and cancer outcomes were tested using logistic regression (stage, route to diagnosis) and parametric regression accelerated failure-time models (1-year survival). Results Analyses of 223,422 patients yielded evidence of 37 "interim diagnoses" across 7 cancer sites that were consistently associated with worse (n=18) or better (n=8) cancer outcomes, or a mixture of worse and better outcomes within or between cancer sites (n=11). For example, gastro-oesophageal reflux disease, gastritis, oesophagitis, or peptic ulcer were associated with worse outcomes in pancreatic, colorectal and ovarian cancers, with better outcomes in stomach cancer, and a mixture in oesophageal cancer. Conclusion We characterise 37 "interim" diagnoses as potential missed opportunities in cancer diagnosis. Safety-netting around these non-cancer diagnoses, focussing on management of clinical uncertainty and robust patient follow-up, may help avoid missed opportunities to diagnose cancer and improve outcomes.
Authors
- Mel Ramasawmy (ORCID: https://orcid.org/0000-0002-4864-8565)
- Luke T. A. Mounce (ORCID: https://orcid.org/0000-0002-6089-0661)
- Sarah J Price (ORCID: https://orcid.org/0000-0002-2228-2374)
- Brian David Nicholson (ORCID: https://orcid.org/0000-0003-0661-7362)
- Georgia Bell Black (ORCID: https://orcid.org/0000-0003-2676-5071)
- Claire Friedemann Smith (ORCID: https://orcid.org/0000-0001-9934-5882)
- Gary Abel (ORCID: https://orcid.org/0000-0003-2231-5161)
- Anne E. Spencer (ORCID: https://orcid.org/0000-0002-8163-3103)
- Fiona Mary Walter (ORCID: https://orcid.org/0000-0002-7191-6476)
- Esther Nansubuga
- Suzanne Emilie Scott (ORCID: https://orcid.org/0000-0001-5536-9612)
- Deepthi Lavu (ORCID: https://orcid.org/0000-0002-5922-9366)
- B. Wiering (ORCID: https://orcid.org/0000-0001-6708-5705)
- Richard David Neal (ORCID: https://orcid.org/0000-0002-3544-2744)
- William Trevor Hamilton (ORCID: https://orcid.org/0000-0003-1611-1373)
- Sarah F. Moore (ORCID: https://orcid.org/0000-0001-9815-5665)
- Luke Robles
- Angela King
- Georgina Laity
Institutions
- Queen Mary University of London (GB)
- University of Exeter (GB)
- University of Oxford (GB)
Publication Details
- Journal
- British Journal of General Practice
- Published
- 2026-11-02
- DOI
- https://doi.org/10.3399/bjgp.2026.0314
- Primary Topic
- Global Cancer Incidence and Screening
- Type
- article
- Field-Weighted Citation Impact
- 0.00